Skip to main content

AnidasoHub

AnidasoHub provides an AI-powered clinical trial discovery platform that lets patients search for studies by simply talking or texting in their native language, with no forms or medical knowledge required. The assistant, Anida, works over phone calls, text, web chat, and voice across 50+ languages, matching users to thousands of recruiting studies and connecting them directly to research sites. Uniquely, the platform is accessible from any phone without internet and can also be accessed through third-party AI platforms like ChatGPT and Claude.

Union City, United States · HQ
Founded 20253100+ followers
Updated yesterday

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Most patients who would qualify for a clinical trial never learn that a study exists, largely because trial listings are written in dense medical jargon for researchers, not patients. Language barriers, limited internet access, low health literacy, and lack of technology further exclude millions of people from research that could help them, particularly underserved communities.

Solution

AnidasoHub provides an AI-powered assistant called Anida that lets patients discover and connect to clinical trials through natural conversation, in any of 50+ languages. Patients simply call a phone number, send a text, or open a web chat or voice interface, and Anida listens in their native language, asks about their condition and preferences, and searches thousands of recruiting studies in real time. Anida explains each matching study in plain language—what it involves, how long it lasts, what is covered—and shows nearby research sites with eligibility scores so the patient can choose where to be referred. After the patient consents, Anida shares their details with the chosen research site and books the first screening call, while the clinical team takes over from there to ensure continuous support. All phone calls are recorded for compliance, and pre-screening through third-party AI platforms remains anonymous with no personal identifiers collected.

Target Audience

Primary users are patients and caregivers seeking clinical trials, particularly those from underserved, non-English-speaking, or low-literacy communities, as well as research sites and sponsors looking to receive pre-screened, qualified participant referrals.

Features

  • Voice-first conversational AI available via phone call (no internet needed), text message, website chat, and voice chat on any device
  • Natural language processing and multilingual support across 50+ languages, from intake to appointment confirmation
  • Real-time search across thousands of recruiting studies spanning 1,200+ indications including cancer, cardiometabolic disease, rare conditions, and mental health
  • Plain-language explanations of study options, including treatment type, study phase, travel distance, and published research behind each study
  • Eligibility pre-screening with scoring and site matching, showing patients all studies they may qualify for, not just one
  • Consent-based referral system: patient details are shared with research sites only after explicit approval, and a screening call is booked automatically
  • Integration with third-party AI platforms (OpenAI's ChatGPT and Anthropic's Claude) for anonymous pre-screening with a random session code
  • Health information matching across conditions, location, and patient preferences, with calls recorded for quality assurance and compliance
This profile is AI-generated and may contain inaccuracies.